

# Policy workshop

“Towards enhanced EU-US innovation collaboration through policy measures ”

## Business view

on enhancing EU-US innovation collaboration

by **Dr. Nihal Engin VRANA,**  
**Director of Fundamental Research, Protip Medical,**  
**France**

Tuesday January 14<sup>th</sup>, 2015, Brussels, BELGIUM

<http://www.EuUsScienceTechnology.eu/>




## **(Short) Introduction on your EU-US RTDI cooperation case**

- 1. One on-going FP 7 project with an American Institute (BWH, Boston, MA) (IMMODGEL 2013-2017)- BWH receives funding from European Commission (580 K€).**
- 2. One submitted H2020 project with the same Institute is under evaluation (THYBORG).**
- 3. Sponsored Research in the American Institute to start the collaboration (2012).**



# BILAT USA 2.0 IMMODGEL Project

- Project Duration: 4 years (Oct 2013-Sept 2017)
  - Total Budget: 7,465,986.60 €,
  - Requested EU contribution: 5,851,316.10 €
  - Scientific Coordinator: Protip SAS
  - 8 partners in 6 Countries
- [www.immodgel.org](http://www.immodgel.org)



## H2020 THYBORG Proposal



### THYBORG

Integration of Engineered Tissues and Mechanical Components as Implantable Smart Responsive HYBRid Bio-Artificial ORGans

#### List of participants

| Participant Name | Participant organisation name                            | Country        |
|------------------|--|----------------|
| 1 (Coordinator)  | Protip SAS   | France         |
| 2                | University of Nottingham                                 | United Kingdom |
| 3                | Max Planck Institute for Intelligent Systems             | Germany        |
| 4                | Harvard Medical School- Brigham and Women's Hospital     | United States  |
| 5                | Middle East Technical University                         | Turkey         |
| 6                | Politecnico di Torino                                    | Italy          |
| 7                | University of Strasbourg                                 | France         |
| 8                | University of Pisa                                       | Italy          |
| 9                | Kirkstall Ltd.   | United Kingdom |
| 10               | CEA-LETI   | France         |
| 11               | Biodevice Systems  | Czech Republic |
| 12               | Tensive  | Italy          |
| 13               | Steinbeis-Europa-Zentrum from Steinbeis Innovation gGmbH | Germany        |



## **(Short) Introduction on your EU-US RTDI cooperation case-Business Expectations**

1. We expect to have 2 products as the outcome of the project. One of the products (An on-chip system) will have heavy input from the US partner.
2. We expect to commercialise these two products on the both sides of the Atlantic and establish a presence in U.S.A.
3. The current condition of the collaboration induced us to develop another project; i.e. we see this route as a feasible one for our business development



## **Challenge(s) encountered (*mainly those that can be addressed through policy measures*)**

- 1. *Lack of Common Documentation: concerning audits, participant balances, Consortium Agreement etc.***
- 2. *Which country's law will be the governing law for Multi-national Consortia? (Belgium is established for European Consortia, but When you have an American Partner, is it still applicable?)***
- 3. *Discussion on the IP issues was long, cumbersome and has not been adequately finalised. No clear definitions for the foreground production and exploitation of results for such collaborations.***
- 4. *Differences in Overhead practices and Institute Contribution (% of Funding Body Contribution)***



## **Policy measures that would help tackling with those challenges**

- 1) Defining legal document equivalencies to help the administration to handle the collaboration properly for the both sides.**
- 2) A common Help Desk or a similar organization to mediate and advise the formation of the collaboration from early stages.**
- 3) Incentives, particularly for SMEs, to establish such collaborations – Tax exemptions, Ease of Establishing a branch in USA or EU, Ease of access to NIH or EU fundings etc.**
- 4) For the Health Sector, Synchronisation of FDA approval and CE-mark obtainment for the applications that are results of collaborations**








## Expectations for future cooperation

- 1. Impactful Research and Breakthrough Products by tapping into the Synergy of Multinational-Transatlantic Research**
- 2. Wider Collaborations, including USA SMEs, to expand our network.**
- 3. Establish a presence in USA.**





- Product to be introduced to the US Market
  - ✓ For Swallowing Disorders
  - ✓ Easy Implantation with an Introducer
  - ✓ Removable



1

2

3

New Breez



**Thank you for your attention**





PROTIP SAS

Dr. Nihal Engin Vrana

*8, Place de l'Hôpital*

*67000 Strasbourg/ France*

*Tel : +33 (0) 3.88.10.30.63*

*Fax : +33 (0) 3.88.32.92.09*

e-mail: [e.vrana@protipmedical.com](mailto:e.vrana@protipmedical.com)

Website:

[www.protipmedical.com](http://www.protipmedical.com)

